# A Study YL201 in Patients With Selected Advanced Solid Tumors

Source: https://onco.cc/trials/nct06057922/  
OnCo record `nct06057922` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of YL201 for Injection in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., active and no longer recruiting.

## Summary

A Study YL201 in Patients With Selected Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06057922 by MediLink Therapeutics (Suzhou) Co., Ltd., with 990 participants enrolled, started 2023-09-22 and due to reach its primary completion in 2026-10. Interventions recorded: YL201 for Injection.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06057922
- Phase: 1/2
- Setting: A Multicenter, Open-Label, Phase 1/2 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With Selected Advanced Solid Tumors
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Enrolled: 990

## Sources

- ClinicalTrials.gov NCT06057922: https://clinicaltrials.gov/study/NCT06057922

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06057922.json